-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2024-519404-27-00
5
2026-01-16
IDH-mutant grade 2 or 3 astrocytoma
-
2024-519798-20-00
4
2026-01-15
pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2024-519829-38-00
5
2026-01-09
Heart failure due to systemic left ventricular systolic dysfunction
-
2024-518167-35-01
4
2025-12-19
Patients with Metastatic Osteosarcoma
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2025-520730-28-00
4
2025-12-08
Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2024-512577-27-00
5
2025-12-02
Chronic kidney disease in paediatric patients
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2024-519590-19-00
4
2025-11-25
PD-L1 positive advanced colorectal cancer
-
2025-521706-17-00
4
2025-11-25
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
-
2024-519261-21-00
4
2025-11-21
Desmoplastic small round cell tumor
-
2024-518583-13-00
6
2025-11-18
Patients with bacteremia
-
2024-512849-17-00
5
2025-11-14
Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis